Q-omics provides the consensus-scored UPK3BP1 profile across patient tissues and cancer cell-line models. UPK3BP1 expression is associated with patient survival in 15 of 34 cancer types, with the highest sampling consensus in STAD. Among the 18 cancer types available for tumor–normal comparison, UPK3BP1 is differentially expressed in 8, with the highest sampling consensus in KIRP. Additionally, UPK3BP1 RNA expression shows 9,538 significant gene co-expression associations, with the highest sampling consensus in THYM. Together, these results highlight STAD, KIRP, and THYM as cancer lineages where UPK3BP1 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for UPK3BP1 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes UPK3BP1 survival associations across molecular data types. UPK3BP1 RNA expression shows survival associations in the most cancer types (15). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible UPK3BP1 RNA expression–survival associations across cancer types. High UPK3BP1 expression shows unfavorable associations in KIRP, PAAD and LGG, but favorable associations in STAD, LUSC and SKCM. The STAD Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p = .009). Together, the overview and detailed table identify STAD as the clearest survival context for UPK3BP1 RNA expression.
This table summarizes UPK3BP1 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 8. The strongest signals are observed in KIRC for RNA.
This table ranks reproducible tumor–normal expression differences for UPK3BP1. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. UPK3BP1 shows higher tumor expression in KIRP, KIRC, STAD, BRCA, BLCA and LUSC. The KIRP box plot shows higher UPK3BP1 RNA expression in tumor versus normal tissue (log2 FC = +0.102, t-test p < 0.001).
This table shows molecular features associated with UPK3BP1 in patient tissues and cancer cell lines. In patient samples, UPK3BP1 shows the broadest associations at the RNA and protein expression levels, with THYM recurring as the lineage with the largest associated feature set.
